No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
DHX240517P3000
- 0.50
- -0.12-19.35%
15min DelayClose May 17 15:59 ET
0.50High0.50Low
0.50Open0.62Pre Close4 Volume33 Open Interest3.00Strike Price200.00Turnover0.00%IV2.04%PremiumMay 17, 2024Expiry Date0.55Intrinsic Value100Multiplier-1DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma4.90Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
Express News | NYSE Order Imbalance 149626.0 Shares on Sell Side
DHI Group(DHX.US) Director Sells US$29,215.17 in Common Stock
$DHI Group(DHX.US)$ Director Swann Kathleen M. sold 11,733 shares of common stock on May 14, 2024 at an average price of $2.49 for a total value of $29,215.17.Source: Announcement What is statement of
DHI Group's Resilience and Growth Potential Affirm Buy Rating
DHI Group | 10-Q: Quarterly report
DHI Group Inc (DHX) Q1 2024 Earnings: Misses Revenue and Net Income Estimates
Barrington Research Maintains Outperform on DHI Group, Maintains $7 Price Target
Barrington Research analyst Gary Prestopino maintains DHI Group (NYSE:DHX) with a Outperform and maintains $7 price target.
Comments
$DHI Group(DHX.US$ Great momentum and fundamental play but no fuel to break the resistance @$2.8 with huge volume. I think it wll test lower level $2 before making next big move.
DHI Group's high P/E ratio is alarming due to its falling earnings and bleak growth forecast. Investors expecting a business revival may be let down if the P/E aligns with the negative growth. The anticipated future earnings may not sustain the high P/E, risking shareholders' investments and potential investors might overpay.
1
Gainers:
• $Repare Therapeutics(RPTX.US$ +26.4% (announces worldwide license and collaboration agreement with Roche for camonsertib)
• $Chewy(CHWY.US$+19.8% (Chewy stock soars on earnings. Here's what really mattered)
• $UiPath(PATH.US$ +11.7% ( reported first-quarter revenue growth of 32% year-over-year to $245.1 million)
• $Pure Storage(PSTG.US$ +10.6% (In reaction to earnings)
• $Credo Technology(CRDO.US$ +10.2% (In reaction ...
• $Repare Therapeutics(RPTX.US$ +26.4% (announces worldwide license and collaboration agreement with Roche for camonsertib)
• $Chewy(CHWY.US$+19.8% (Chewy stock soars on earnings. Here's what really mattered)
• $UiPath(PATH.US$ +11.7% ( reported first-quarter revenue growth of 32% year-over-year to $245.1 million)
• $Pure Storage(PSTG.US$ +10.6% (In reaction to earnings)
• $Credo Technology(CRDO.US$ +10.2% (In reaction ...
19
$DHI Group(DHX.US$ pump is coming
Read more